673 reports of this reaction
1.8% of all KETOPROFEN reports
#8 most reported adverse reaction
INFUSION SITE PAIN is the #8 most commonly reported adverse reaction for KETOPROFEN, manufactured by Allegis Pharmaceuticals, Inc.. There are 673 FDA adverse event reports linking KETOPROFEN to INFUSION SITE PAIN. This represents approximately 1.8% of all 36,564 adverse event reports for this drug.
Patients taking KETOPROFEN who experience infusion site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE PAIN is a less commonly reported adverse event for KETOPROFEN, but still significant enough to appear in the safety profile.
In addition to infusion site pain, the following adverse reactions have been reported for KETOPROFEN:
The following drugs have also been linked to infusion site pain in FDA adverse event reports:
INFUSION SITE PAIN has been reported as an adverse event in 673 FDA reports for KETOPROFEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE PAIN accounts for approximately 1.8% of all adverse event reports for KETOPROFEN, making it a notable side effect.
If you experience infusion site pain while taking KETOPROFEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.